Goldman Sachs CEO David Solomon says bitcoin could be 'a store of value case'
The Goldman Sachs CEO joined CNBC for an interview from the Summer Olympics in Paris, France.“I’ve always said I think it’s a speculative investment,” David Solomon said. “I don’t see a real use case.”
David Solomon, the chief executive of Goldman Sachs, is not one to speculate on the price of bitcoin or any other crypto assets.
"I've always said I think it's a speculative investment," Solomon said during an interview with CNBC at the Summer Olympics in Paris, France. "I don't see a real use case."
Solomon said the underlying technology behind crypto is "super interesting," highlighting how progress can be made to take the friction out of the financial system as the system becomes increasingly digitized.
When asked by CNBC's Joe Kernan if building a reserve similar to a gold reserve is a store of value case or a use case for Bitcoin BTC -3.88% , Soloman said "there very well could be a store of value case."
In 2021, the same year Goldman Sachs launched a crypto desk, Solomon said, "Bitcoin is on an inevitable path to have the same market capitalization and then a higher one than gold."
The price of bitcoin is up about 490% over the past five years and trades around $66,237, according to The Block's BTC price page . The spot price of gold is up about 67% in that same period.
Goldman's role in crypto
Despite Solomon's more tepid comments Tuesday, 2024 is shaping up to be a big year for Goldman's push into the crypto space. Earlier this year, Goldman Sachs was among several firms to have completed a series of tests on Canton Network, an interoperable "network designed for institutional assets" created by Digital Asset Holdings.
In a fireside chat in March at the Digital Asset Summit in London, Mathew McDermott, Goldman's global head of digital assets, said the company has been actively investing in the digital asset space and "looking at the bankruptcy claims and other investing opportunities."
The bank confirmed it had seen growing interest from hedge fund clients in crypto-related products.
“Many of our largest clients are active or exploring getting active in the space,” Max Minton, Asia Pacific head of digital assets of Goldman Sachs, told Bloomberg. This came near the height of the post-spot bitcoin ETF launches.
On July 10, it was reported that Goldman Sachs plans to launch three tokenization projects by the end of the year, focused on U.S. and European markets. The firm is also said to be planning to create marketplaces for tokenized assets.
"Central banks are looking at digital currencies, working to apply this technology to the local markets and determine the longer-term impact on global payment systems," Solomon said during an earnings call in April 2021. "Also significant focus on cryptocurrencies like Bitcoin, where the trajectory is less clear as market participants evaluate their possibility as a store of value."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
